Amphastar Pharmaceuticals, Inc. cash flow to debt ratio of 23.80% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Amphastar Pharmaceuticals, Inc.'s free cash flow has decreased -29.66% from $172.34M last year to $121.23M, signaling decreasing performance

Amphastar Pharmaceuticals, Inc.'s debt to equity ratio is 0.89, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Amphastar Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.89 last year to 0.89 today, signaling weakened financials

Amphastar Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 2.29x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Amphastar Pharmaceuticals, Inc.'s interest coverage ratio of 4.53 indicates that earnings with good margin can cover interest payments on company debt

Amphastar Pharmaceuticals, Inc.'s profit margin has decreased (-49.54%) in the last year from 21.79% to 11.00%, signaling decreasing performance

Amphastar Pharmaceuticals, Inc.'s short-term assets of $636.02M exceed its short-term liabilities of $158.16M

Amphastar Pharmaceuticals, Inc.'s return on assets of 4.81% is lower than the 5.00% threshold, indicating inefficient asset utilization

Amphastar Pharmaceuticals, Inc.'s return on equity of 10.23%, is lower than 15.00%, indicating bad performance

Amphastar Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Amphastar Pharmaceuticals, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Amphastar Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Amphastar Pharmaceuticals, Inc. has a free cash flow yield of 14.62%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Amphastar Pharmaceuticals, Inc.'s yearly earnings has decreased -38.51% since last year from $159.52M to $98.09M, signaling decreasing performance

Amphastar Pharmaceuticals, Inc.'s yearly revenue has increased 0.99% since last year from $712.81M to $719.89M, signaling increasing performance

ROIC 6.02% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Amphastar Pharmaceuticals, Inc.'s 3-year revenue CAGR of 12.99% is positive, indicating growing revenue over the past 3 years

Amphastar Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Amphastar Pharmaceuticals, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Amphastar Pharmaceuticals, Inc. is undervalued relative to its fair value price of 36.26 based on Discounted Cash Flow model

Amphastar Pharmaceuticals, Inc. has an earnings yield of 9.29%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Amphastar Pharmaceuticals, Inc. is overvalued relative to its fair value price of 12.15 based on EBITDA multiple model

Amphastar Pharmaceuticals, Inc. has an EV/EBITDA ratio of 6.19x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Amphastar Pharmaceuticals, Inc. is undervalued relative to its fair value price of 64.48 based on Earnings Fair Value model

Amphastar Pharmaceuticals, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

Amphastar Pharmaceuticals, Inc. has a price-to-book ratio of 1.10x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Amphastar Pharmaceuticals, Inc. has a price-to-sales ratio of 1.18x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue